Page 1 | Search Results | Blood | American Society of Hematology

Skip to Main Content

Skip Nav Destination

1-2 of 2

Sort by

Sort Order Select

Journal Articles

Randomized Phase 2 Trial of the Anti-PD-L1 Monoclonal Antibody Durvalumab Plus Lenalidomide Versus Single-Agent Durvalumab in Patients with Refractory/Advanced Cutaneous T Cell Lymphoma

Christiane Querfeld, Lu Chen, Xiwei Wu, Zhen Han, ChingYu Su, Melissa Banez, Jeralyn Quach, Tiffanie Barnhizer, Liliana Crisan, Steven T. Rosen, Jasmine Zain

Blood (2024) 144 (Supplement 1): 468.

https://doi.org/10.1182/blood-2024-205617

Published: 2024

Journal Articles

Preliminary Analysis Demonstrates Durvalumab (Anti-PD-L1) & Lenalidomide Is Superior to Single-Agent Durvalumab (anti-PD-L1) in Refractory/Advanced Cutaneous T Cell Lymphoma in a Randomized Phase 2 Trial

Christiane Querfeld, Lu Chen, Xiwei Wu, Zhen Han, ChingYu Su, Melissa Banez, Jeralyn Quach, Tiffanie Barnhizer, Liliana Crisan, Steven T. Rosen, Jasmine M. Zain

Blood (2023) 142 (Supplement 1): 3077.

https://doi.org/10.1182/blood-2023-188053

Published: 2023